New vaccine aims to wake up immune system against hepatitis b

NCT ID NCT07204236

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new vaccine called TVAX-008 in 20 adults with chronic hepatitis B who have very low levels of the virus. The goal is to see if the vaccine can safely boost the body's immune response, potentially helping control the infection. Participants will be monitored for changes in hepatitis B antibodies and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TVAX-008 injection

What this could lead to

If it works, this could point toward a way to help the immune system control chronic hepatitis B without lifelong medication.

What could go wrong

This is a very early, small trial (20 people) focused on safety and immune response. It may not lead to a treatment, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shandong Province Public Health Clinical Center

    Jinan, Shandong, 250000, China